Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy

Jung Gil Park; Soo Young Park

doi:10.3350/cmh.2015.21.3.242

Clin Mol Hepatol > Volume 21(3); 2015 > Article

Park and Park: Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy

Original Article

Clinical and Molecular Hepatology 2015; 21(3): 242-248.

Published online: September 30, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.3.242

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy

Jung Gil Park¹, Soo Young Park²

Corresponding author: Soo Young Park. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea.
Tel: +82-53-200-5519, Fax: +82-53-426-8773, psyoung0419@gmail.com

Received July 20, 2015 Revised August 20, 2015 Accepted August 25, 2015

(open-access, http://creativecommons.org/licenses/by-nc/3.0/):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background/Aims

We compared the efficacies of entecavir (ETV) plus tenofovir (TDF) and ETV plus adefovir (ADV) in chronic hepatitis B (CHB) patients with genotypic resistance to lamivudine (LAM) who showed a suboptimal response to LAM and ADV combination therapy.

Methods

We reviewed 63 CHB patients with genotypic resistance to LAM who showed a suboptimal response to LAM and ADV combination therapy. Among these patients, 30 were treated with ETV + ADV and 33 were treated with ETV + TDF for 12 months.

Results

The only baseline characteristic that differed significantly between the two groups was the ETV resistance profile. The rate of a virologic response [serum hepatitis B virus (HBV) DNA level of <20 IU/mL] was significant higher for ETV+TDF than for ETV+ADV over 12 months (57.6% vs. 23.3%, P=0.006, at 6 months; 84.8% vs. 26.7%, P<0.001, at 12 months). The probability of a virologic response was significantly increased in ETV+TDF (P<0.001, OR=54.78, 95% CI=7.15-419.54) and decreased in patients with higher baseline viral loads (P=0.001, OR=0.18, 95% CI=0.07-0.50) in multivariate analysis. No serious adverse event occurred during the study period.

Conclusions

In patients with CHB who showed a suboptimal response to LAM and ADV combination therapy, ETV+TDF was superior to ETV+ADV in achieving a virologic response regardless of the HBV resistance profile. Further large-scale and long-term follow-up prospective studies are needed to explain these results.

Keywords: Chronic hepatitis B; Lamivudine resistance; Combination therapy; Entecavir; Tenofovir

INTRODUCTION

During the recent two decades, neucleos(t)ide analogues (NAs) have been a cornerstone in the treatment of chronic hepatitis B (CHB), targeting the reverse transcription of hepatitis B virus (HBV) polymerase.1 2 3 A high level of serum HBV DNA is known to be associated with the progression of hepatic fibrosis and the development of hepatocellular carcinoma (HCC).4 5 The wide use of antiviral agents with a low genetic barrier, such as lamivudine (LAM), adefovir (ADV), telbivudine, and clevudine (in Korea), as the first treatment option is one of main causes of the high prevalence of genotypic resistance to NAs among CHB patients in Asian countries.6 Especially, switching to ADV monotherapy instead of an add-on therapy increased the number of CHB patients with multidrug resistance or a suboptimal response to NA combination therapy.6 7 8 9 Sequential ADV monotherapy after the emergence of LAM resistance failed to achieve an adequate virologic response in up to 25% of patients and additionally caused the development of genotypic resistance.10 11 LAM and ADV combination therapy has also failed to achieve complete response in approximately 70% of LAM-resistant CHB patients.7 12 A suboptimal response to antiviral therapy might result in a higher risk of developing resistance to multiple NAs, leading to an increased risk of end-stage liver disease and HCC.13 14 Therefore, most guidelines suggest that the ideal treatment for CHB is to reduce the serum HBV DNA level to below the detection limit of real-time polymerase chain reaction (PCR).1 3 There is little consensus on the adequate antiviral therapy for CHB patients showing a suboptimal response after LAM and ADV combination therapy. Before the approval of tenofovir (TDF), entecavir (ETV)+ADV was the most potent combination therapy for CHB patients with a suboptimal response to LAM and ADV therapy.15 As TDF was available in clinical practice, it became an important potent NA used as an antiviral regimen against CHB.16

Therefore, in this study, we aimed to compare the efficacy of ETV and TDF combination therapy with that of ETV and ADV therapy in CHB patients with genotypic resistance to LAM who showed a suboptimal response to LAM and ADV combination therapy.

PATIENTS AND METHODS

Eligible patients

We reviewed 258 CHB patients who developed genotypic resistance to LAM during LAM therapy at Kyungpook National University Hospital and Kyungpook National University Medical Center between 2009 and 2011, and identified 63 patients with a suboptimal response to LAM and ADV combination therapy.

The inclusion criteria were CHB patients (i) with serum HBV DNA level of >20 IU/mL during at least 3-month intervals after the treatment with LAM and ADV for at least 12 months, (ii) those with documented genotypic resistance to NAs, and (iii) those aged from 16 to 80 years.

The exclusion criteria were patients with (i) coinfection of chronic hepatitis C virus or human immunodeficiency virus; (ii) serum creatinine level of >1.5 mg/dL; (iii) decompensated liver cirrhosis; (iv) HCC; (v) diagnosis of a malignancy other than HCC within 3 years or an untreated malignancy; (vi) current alcohol or substance use; and (vii) major organ transplantation including the heart, lungs, and kidneys.

Study design

Of the 63 patients with a suboptimal response to the combination of LAM and ADV during at least 12 months, 30 patients received ETV and ADV (ETV+ADV group) and the remaining 33 patients received ETV and TDF (ETV+TDF group). We evaluated the liver function parameters, serum creatinine level, HBeAg positivity, prothrombin activity, platelet counts, and imaging tests for the diagnosis of liver cirrhosis. The serum HBV DNA level was quantified with a real-time PCR assay (Amplicor HBV Monitor Test; Roche Diagnostics, Basel, Switzerland; detection limit, ~12 IU/mL). Serum blood samples were stored for the analysis of the resistance profile of NAs. Multiplex restriction fragment mass polymorphism assays of the HBV genome were done to analyze the genotypic resistance profiles at baseline.

The primary end-point of the study was the rate of virologic response at 12 months (VR12, serum HBV DNA <20 IU/mL in realtime PCR). The secondary end-points included virologic response at 6 months (VR6, serum HBV DNA <20IU/mL in real-time PCR), serum HBV DNA reduction during the follow-up period, factors associated with VR12, and the rate of loss or seroconversion of HBeAg in patients with the antigen. The study protocol was approved by the local ethics committee and was conducted in accordance with the principles of the Declaration of Helsinki.

Definition of treatment response

The serum HBV DNA level was assessed every 3 months during the first 12 months. Virologic response was defined as a serum HBV DNA level of <20 IU/mL. Suboptimal response was defined as a decrease in serum HBV DNA level of >2 log₁₀ IU/mL at 24 and 48 weeks after therapy without a virologic response. The upper limit of normal alanine aminotransferase (ALT) was defined as 30 IU/L in men and 19 IU/L in women.

Statistical analysis

The variables were expressed as mean with standard deviation, or number with percentage. Categorical and continuous variables between groups were analyzed by using the chi-square test and Student t-test, respectively. The cumulative probability of VR12 during treatment was calculated with the Kaplan-Meier method and compared with a log-rank test. The mean reductions of serum DNA level between the groups were analyzed by using the Student t-test. Factors related to achieving VR12 were analyzed by using the logistic regression model with backward elimination. P-values <0.05 ware considered statistically significant. All data were analyzed by using SPSS (version 20.0; IBM, Somers, NY, USA).

RESULTS

Baseline characteristics of the patients

A total of 63 patients were included in the study. Thirty patients were treated with a combination of ETV and ADV (ETV+ADV group), and 33 patients were treated with a combination of ETV and TDF (ETV+TDF group). There was no significant difference between the two groups except for ETV resistance mutation (Table 1). Overall, 55 (87%) patients were HBeAg positive and 24 patients were found to have liver cirrhosis on the basis of ultrasonography findings. The mean serum HBV DNA level of the patients was 4.61 log₁₀ IU/mL at baseline. In the HBV mutation test at baseline, all patients had a LAM resistance mutation, including rtM204V/I (n=61, 96.8%) and rtL180M (n=43, 68.3%). Approximately half of the patients had an ADV resistance mutation, including rtA181V/T (n=30, 48%) and rtA181V/T+rtN236T (n=9, 14%). Although it was observed in a relatively small proportion of patients, ETV resistance mutation was more frequent in the ETV+TDF group than in the ETV+ADV group (n=4, 13% vs. n=12, 36%; P=0.036). However, there was no significant difference between the two groups in multidrug resistance, defined as the presence of resistance mutation with LAM+ADV or LAM+ETV (n=17, 57% vs. n=20, 61%; P=0.751).16

Virologic response

The primary end-point, the proportion of patients who achieved VR12, was significantly different between the two groups (26.7% vs. 84.8%, P<0.001) (Table 2, Fig. 1). The rate of patients who achieved VR6 was significantly higher in the ETV+TDF group than in the ETV+ADV group (23.3% vs. 57.6%, P=0.006). In univariate analysis for factors associated with achieving VR12, a lower serum baseline HBV DNA level and rescue therapy with ETV+TDF were associated with achieving VR12 (Table 3). In multivariate analysis with the logistic regression model, patients with a lower baseline serum HBV DNA level (odd ratio [OR], 0.19; 95% CI, 0.07-0.50; P=0.001) and rescue therapy with ETV+TDF (OR, 54.78; 95% CI, 7.15-418.54; P<0.001) had a significantly higher probability of achieving VR12. However, the HBV resistance mutation profiles, including ADV, ETV, and multidrug resistance, were not associated with VR12 in both univariate and multivariate analyses.

The serum HBV DNA level tended to decrease more in the ETV+TDF group than in the ETV+ADV group (Table 2, Fig. 2). Both the ETV+ADV and ETV+TDF groups showed an initial rapid reduction of serum HBV DNA level during the first 3 months (2.12 log₁₀ IU/mL vs. 2.00 log₁₀ IU/mL, P=0.731). While the serum HBV DNA level showed further decreases at 9 months in the ETV+TDF group (2.40 log₁₀ IU/mL vs. 3.02 log₁₀ IU/mL, P=0.057), the serum HBV DNA level at 12 months did not differ significantly between the ETV+ADV and ETV+TDF groups (2.60 log₁₀ IU/mL vs. 3.02 log₁₀ IU/mL, P=0.224).

Biochemical and serologic response

The proportions of patients with serum ALT normalization at 12 months did not differ significantly between the ETV+ADV and ETV+TDF groups (63% vs. 67%, P=0.782) (Table 2). HBeAg loss or HBeAg seroconversion was not observed among the HBeAg-positive patients in both groups (Table 2).

Safety

No serious adverse effects of antiviral agents were observed during the treatment period in both groups. None of the patients experienced elevation of serum creatinine of ≥0.5 mg/dL or a serum ALT flare-up (>10-fold of the normal upper limit). All patients continued antiviral agent treatment without dose interruption.

DISCUSSION

After the approval of ETV and TDF, the management of CHB has markedly improved during the last decade.1 2 3 ETV and TDF, which have a high genetic barrier to resistance development, are the most potent NAs for the suppression of viral load in CHB patients.17 18 The 5-year resistance rate to ETV and TDF was reported to be 1.2% and 0%, respectively, in NA-naïve CHB patients17 18 However, in cases with the presence of LAM resistance, this profile is disappointing. In patients with LAM-resistant CHB, ETV monotherapy showed virologic, serologic, and biochemical improvement for 48 weeks.19 20 As LAM-resistant HBV is less susceptible to ETV, the probability of achieving an adequate virologic response is lower in patients with LAM-resistant HBV than in NA-naïve patients.19 20 Moreover, the emergence of ETV resistance mutation is more frequently observed during the long-term treatment of patients with LAM resistance.20 In this regard, previous multiple sequential monotherapy or use of NAs with a low genetic barrier induced the sequential development of resistance mutations. Multidrug resistance not only led to viral breakthrough but also limited the future therapeutic options. For these reasons, appropriate combination therapies are important in patients with multidrug-refractory CHB.

In a prior study, the combination of ETV and ADV was shown to suppress HBV replication significantly without the development of additional resistance mutation for 52 weeks in suboptimal responders to LAM and ADV.21 However, the proportion of virologic response was only 28.9% in patients treated with ETV and ADV combination therapy, which was similar to the results of our study. In the present study, the treatment for 1 year with the combination of ETV and TDF showed a significantly higher proportion of achieving VR12 than the combination of ETV and ADV in patients with NA-resistant HBV who showed suboptimal responses to the combination of LAM and ADV (ETV+ADV, 26.7% vs. ETV+TDF, 84.8%). However, the genotypic resistance profiles, including LAM, ADV, ETV, and multidrug resistance, did not affect the cumulative probability of achieving VR12. In the subgroup analysis, 9 patients with the rtA181T/V+rtN236T double mutation at baseline were treated with ETV+ADV (n=5) or ETV+TDF (n=4). HBV with rtA181T/V+rtN236T double mutation is known to reduce the virologic response in the treatment with TDF or with a combination of LAM and TDF in patients with a prior failure of LAM and ADV combination therapy.22 However, in patients with the rtA181T/V+rtN236T double mutation at baseline, the proportion of VR12 was similar to those of the entire study population (ETV+ADV, 40% vs. ETV+TDF, 75%, data not shown). This result was supported by a recent study that showed a negative association between predictors of virologic response and the genotypic resistance profile during ETV+TDF combination therapy.23 In another subgroup analysis, 6 patients with LAM, ETV, and ADV resistance mutation at baseline were treated with ETV+ADV (n=2) or ETV+TDF (n=4). Three patients (75%) who were treated with ETV+TDF achieved VR12, whereas none of the patients treated with ETV+ADV achieved VR12 (data not shown). However, these subgroup analyses were limited by the relatively small number of patients. Liver cirrhosis and HBeAg positivity also did not affect the suppression of HBV DNA level during the antiviral therapy. Only higher baseline HBV DNA levels independently predicted an unfavorable virologic response during the treatment with the combination of ETV and TDF. HBeAg loss or HBeAg seroconversion was not observed among patients with HBeAg at baseline during the entire study period. Although the mechanism was unknown, this result suggests that it is difficult to achieve serologic response in patients with a suboptimal response to LAM and ADV, regardless of rescue therapy.19 21 24

TDF, which is metabolized by the kidneys, may induce renal proximal tubulopathy and cause renal tubular dysfunction.25 In the present study, no worsening of renal function was observed in patients during the antiviral therapy.

This study has some limitations owing to its retrospective design. In the baseline genotypic resistance profiles, ETV resistance mutation was more frequently found in patients treated with ETV and TDF. However, a previous study showed that genotypic resistance to ETV did not associate with the probability of virologic response during TDF rescue therapy.26 In addition, in a recent study that showed the efficacy of ETV and TDF combination therapy for multidrug-resistant CHB patients, the proportion of achieving VR12 was 79.6%, which was similar to the results in our study. The other limitations were the short study duration and the requirement for the evaluation for subsequent genotypic resistance mutation at 12 months. At present, although the development of subsequent genotypic mutation after an ETV and TDF combination therapy is not well known, a relatively high rate of VR12 could be expected to lower the possibility of additional genotypic mutation development.13 14 Nevertheless, further long-term prospective studies might be needed to investigate the subsequent development of genotypic mutation.

In summary, this study demonstrated that the efficacy of ETV and TDF combination therapy is significantly higher than that of ETV and ADV combination therapy in patients with NA-resistant CHB who showed a suboptimal response to LAM and ADV. Regardless of the HBV genotypic resistance profile, the baseline serum HBV DNA level was independently associated with the cumulative probability of achieving virologic response during rescue therapy in patients who failed treatment with LAM and ADV. Because of the absence of important adverse effects or dose interruption, ETV and TDF were continued during the study period.

In conclusion, regardless of the HBV genotypic resistance profile, the efficacy of the ETV and TDF combination therapy is superior to that of ETV+ADV in patients with NA-resistant CHB who showed a suboptimal response to both LAM and ADV.

Acknowledgements

JGP and SYP designed the study and critically revised the manuscript; JGP collected and analyzed data; JGP and SYP drafted the manuscript

FOOTNOTES

Conflicts of Interest: The authors have no conflicts to disclose.

Abbreviations

ADV

adefovir

ALT

alanine aminotransferase

CHB

chronic hepatitis B

ETV

entecavir

HBV

hepatitis B virus

HCC

hepatocellular carcinoma

LAM

lamivudine

NAs

neucleos(t)ide analogues

PCR

polymerase chain reaction

TDF

tenofovir

VR6

virologic response at 6 months

VR12

virologic response at 12 months

REFERENCES

1. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242. 19054588.

2. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-1341. 18845489.

3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662. 19714720.

4. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. 16391218.

5. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686. 16530509.

6. Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-861. 14999707.

7. Peters MG, Hann Hw Hw, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101. 14699491.

8. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2:87-106. 15017613.

9. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39(Suppl 1):S3-S25. 14708673.

10. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283-290. 16338024.

11. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-313. 17256746.

12. Fung J, Lai CL, Yuen JC, Wong DK, Tanaka Y, Mizokami M, et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir Ther 2007;12:41-46. 17503746.

13. Lampertico P. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice. J Hepatol 2009;50:644-647. 19231017.

14. Santantonio T, Fasano M, Durantel S, Barraud L, Heichen M, Guastadisegni A, et al. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. Antivir Ther 2009;14:557-565. 19578241.

15. Lim YS, Lee TH, Heo NY, Shim JH, Lee HC, Suh DJ. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues. Antivir Ther 2012;17:53-60. 22267469.

16. Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, et al. Entecavir plus tenofovir combination as rescue therapy in pretreated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012;56:520-526. 22037226.

17. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514. 19280622.

18. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-475. 23234725.

19. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-1209. 16230074.

20. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008;48:99-108. 18537189.

21. Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, et al. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis b who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother 2012;56:2941-2947. 22430972.

22. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011;60:247-254. 21036792.

23. Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM, et al. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis b patients with multidrug-resistant strains. Antimicrob Agents Chemother 2014;58:6710-6716. 25155601.

24. Peters MG, Hann Hw Hw, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101. 14699491.

25. Gracey DM, Snelling P, McKenzie P, Strasser SI. Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther 2013;18:945-948. 23839869.

26. Kim YJ, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, et al. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. World J Gastroenterol 2012;18:6996-7002. 23322999.

Figure 1

Proportions of patients with a virologic response (serum HBV DNA <20 IU/ml) in the ETV+ADV and ETV+TDF groups at 12 months.

Figure 2

Mean reductions in serum HBV DNA level at 12 months in the ETV+ADV and ETV+TDF groups in patients with CHB refractory to LAM and ADV combination therapy.

Table 1.

Baseline characteristics of the study patients

Characteristic	Total (N= 63)	ETV+ADV (N= 30)	ETV+TDF (N= 33)	P-value
Male gender, no (%)	50 (79.3)	26 (86.7)	24 (72.7)	0.172
Age (years)	49±10	49±10	49±10	0.937
Cirrhosis, no. (%)^*	24 (38.1)	13 (43.3)	11 (33.3)	0.414
Platelet (×10⁹/L)	188±69	186±76	204±61	0.904
ALT (IU/L)	32±19	34±21	29±18	0.319
Total bilirubin (mg/dL)	0.95±0.61	0.95±0.45	0.94±0.72	0.954
Albumin (mg/dL)	4.5±0.4	4.4±0.4	4.5±0.4	0.204
INR (IQR)	1.05±0.11	1.08±0.12	1.03±0.11	0.177
HBeAg-positivity, no (%)	55 (87.3)	25 (83.3)	30 (90.9)	0.367
HBV DNA (log₁₀IU/mL)	4.61±1.14	4.71±1.21	4.51±1.08	0.467
LAM-resistance mutation, no. (%)	63 (100)	30 (100)	33 (100)	1.000
rtM204V/I	61 (96.8)	29 (96.7)	32(97.0)	0.945
rtL180M	43 (68.3)	18 (60.0)	25 (75.8)	0.180
ADV-resistance mutation, no. (%)	30 (47.6)	17 (56.7)	13 (39.4)	0.170
rtA181V/T	30 (47.6)	17 (56.7)	13 (39.4)	0.170
rtA181V/T+rtN236T	9 (14.3)	5 (16.7)	4 (12.1)	0.607
ETV-resistance mutation, no. (%)	16 (25.4)	4 (13.3)	12 (36.4)	0.036
rtS202G	8 (12.7)	1 (3.3)	7 (21.2)	0.033
rtT184I/L/S	7 (11.1)	3 (10.0)	4 (12.1)	0.789
rtM250V/L	3 (4.8)	1 (3.3)	0.612	0.644
Multi-drug resistance, no. (%)^†	37 (58.7)	17 (56.7)	20 (60.6)	0.751
LAM, ADV and ETV-resistance mutation, no. (%)	6 (9.5)	2 (6.7)	4 (12.1)	0.461

^* Cirrhosis was diagnosed by the identification of liver surface nodularity and cirrhosis-related nodules with splenomegaly on ultrasonography.

^† Multi-drug resistance was defined as presence of resistant mutation with LAM+ADV or LAM+ETV.

ETV+ADV, entecavir (1 mg/day)-and-adefovir (10 mg/day) combination therapy group; ETV+TDF, entecavir (1 mg/day)-and-tenofovir (300 mg/day) combination therapy group; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; INR, international normalized ratio; IQR, interquartile range.

Table 2.

Virologic, biochemical, and serologic responses according to the combination treatment

Response	ETV+ADV (n= 30)	ETV+TDF (n= 33)	P-value
Reductions in HBV DNA level, log₁₀ IU/mL^*
3 months	2.12±1.32	2.00±1.24	0.731
6 months	2.12±1.53	2.60±1.10	0.160
9 months	2.40±1.40	3.02±1.05	0.057
12 months	2.60±1.43	3.02±1.29	0.224
Virologic response, no. (%)
3 months	4 (13.3)	10 (30.3)	0.106
6 months	7 (23.3)	19 (57.6)	0.006
9 months	7 (23.3)	25 (75.8)	<0.001
12 months	8 (26.7)	28 (84.8)	<0.001
Normalization of ALT at 12 months, no. (%)^†	19 (63.3)	22 (66.6)	0.782
HBeAg loss at 12 months, no. (%)	0 (0)	0 (0)	-

^* Mean ± standard deviation (SD).

^† Upper limit of normal ALT was defined as 30 IU/L in men and 19 IU/L in women.

HBV, hepatitis B virus; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen.

Table 3.

Analysis of factors predicting the achievement of a virologic response (serum HBV DNA level of <20 IU/mL) at 12 months

Characteristic	Univariate analysis	Multivariate analysis^†
Characteristic	P-value	OR	95% CI	P-value
Male gender	0.106	0.324	0.33-28.93	0.324
Age (per year)	0.430	0.94	0.84-1.05	0.286
Cirrhosis	0.369	0.66	0.08-5.75	0.702
HBeAg positivity	0.743	2.01	0.17-23.45	0.579
Baseline HBV DNA (per log₁₀ IU/ml)	0.001	0.19	0.07-0.50	0.001
LAM+ADV-resistance mutation	0.560	3.01	0.25-35.78	0.383
LAM+ETV-resistance mutation	0.616	1.52	0.09-25.00	0.768
Multi-drug resistance^*	0.941	0.72	0.03-15.91	0.833
Rescue therapy with ETV+TDF	<0.001	54.76	7.15-419.54	<0.001

^* Multi-drug resistance was defined as presence of resistant mutation with LAM+ADV or LAM+ETV.

^† Multivariate analysis was conducted by logistic regression model with backward elimination.

OR, odds ratio; CI, confidence interval; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; LAM+ADV, lamvudine-and-adefovir; ETV+ADV, entecavir-and-adefovir; ETV+TDF, entecavir-and-tenofovir.